Leronlimab Under Evaluation for Potential Treatment of Coronavirus
28. Januar 2020 08:00 ET
|
CytoDyn, Inc.
VANCOUVER, Washington, Jan. 28, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Appoints Maura Fleming as Vice President, General Counsel and Corporate Secretary
23. Januar 2020 08:00 ET
|
CytoDyn, Inc.
VANCOUVER, Washington, Jan. 23, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV
17. Dezember 2019 16:36 ET
|
CytoDyn, Inc.
In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5...
CytoDyn to Hold Investment Community Conference Call on December 17, 2019
11. Dezember 2019 18:17 ET
|
CytoDyn, Inc.
VANCOUVER, Washington, Dec. 11, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
03. Dezember 2019 08:00 ET
|
CytoDyn, Inc.
First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant...
CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model
21. November 2019 06:00 ET
|
CytoDyn, Inc.
VANCOUVER, Washington, Nov. 21, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Engages LifeSci Public Relations as Communications Partner
18. November 2019 08:00 ET
|
CytoDyn, Inc.
VANCOUVER, Wash., Nov. 18, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist...
Uptick Newswire Hosts CytoDyn Inc. on Their Stock Day Podcast to Discuss Revenue Expectations for 2020
11. Februar 2019 08:30 ET
|
CytoDyn, Inc.
PHOENIX, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (CYDY), a biotechnology company developing innovative treatments for multiple therapeutic...
Uptick Newswire Hosts The President and CEO of CytoDyn Inc. to Discuss The Incredible Potential Breakthroughs The Company is Working Towards in HIV and Cancer Treatment
14. Januar 2019 08:30 ET
|
CytoDyn, Inc.
PHOENIX, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (OTC.QB: CYDY) (the “company”), which is a biotechnology company focused on the clinical...
CytoDyn, Inc.’s President and CEO, Nader Pourhassan, Ph.D., Discusses Company Research with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
27. August 2018 07:30 ET
|
CytoDyn, Inc.
PHOENIX, Aug. 27, 2018 (GLOBE NEWSWIRE) -- CytoDyn, Inc. (OTCQB:CYDY), (the “Company”) announced President and CEO Nader Pourhassan’s interview on Uptick Newswire’s “Stock Day” Podcast. Everett...